脂蛋白(a)与2型糖尿病患者的肌肉减少症相关：一项横断面研究。

Lipoprotein(a) is Associated with Sarcopenia in Patients with Type 2 Diabetes: A cross-Sectional Study.

作者信息

Wei Wen, Lv Fenyan, Liu Shuling, Cao Hui, Lin Ruiyu, Chen Hangju, Tu Mei, Cao Baozhen

机构信息

Department of Endocrinology, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, People's Republic of China.

The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510280, People's Republic of China.

出版信息

Diabetes Metab Syndr Obes. 2024 Nov 27;17:4511-4524. doi: 10.2147/DMSO.S489605. eCollection 2024.

DOI:10.2147/DMSO.S489605

PMID:39619221

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11608542/

Abstract

BACKGROUND

The association between lipoprotein(a) (Lp(a)) and sarcopenia in T2DM patients of general age is unclear, and whether this association differs by sex remains uncertain. We intend to analyze the association between Lp(a) and sarcopenia in patients with type 2 diabetes mellitus (T2DM) and whether this association differs by sex.

METHODS

T2DM patients between December 2021 and December 2022 were consecutively enrolled. Sarcopenia was defined according to the criteria of Consensus of the Asian Working Group for Sarcopenia (AWGS) 2019.A multivariable logistic regression model was used to calculate the odds ratio of Lp(a)≥30 mg/dL for sarcopenia in total T2DM patients and in all sexes. Restricted cubic splines were also used to evaluate the association between Lp(a) and sarcopenia.

RESULTS

Among the 426 patients, the mean age was 58.6 years and 56.3% were males. The prevalence of sarcopenia was 31.7% in total patients, 34.2% in male and 28.5% in female. The percentages of Lp(a)≥30 mg/dL were 19.0% in total patients. Compared with patients in Lp(a)<30 mg/dL group, those in Lp(a)≥30 mg/dL group showed an increased risk of sarcopenia (adjusted odds ratio [aOR]: 2.19, 95% CI: 1.09 to 4.39, p = 0.027). Results from restricted cubic splines were robust. When analyzing each sex, there was also a significant association between Lp(a)≥30 mg/dL and sarcopenia (male: aOR: 2.59, 95% CI: 1.09 to 6.21, p = 0.032; female: aOR: 2.45, 95% CI: 1.06 to 6.03, p = 0.039).

CONCLUSION

In T2DM patients, elevated Lp(a) was associated with an increased risk of sarcopenia and such an association did not differ by sex. Screening for sarcopenia should be emphasized in T2DM patients with Lp(a)≥30 mg/dL, both men and women.

摘要

背景

一般年龄的2型糖尿病（T2DM）患者中脂蛋白（a）[Lp（a）]与肌肉减少症之间的关联尚不清楚，且这种关联是否存在性别差异仍不确定。我们旨在分析2型糖尿病（T2DM）患者中Lp（a）与肌肉减少症之间的关联，以及这种关联是否存在性别差异。

方法

连续纳入2021年12月至2022年12月期间的T2DM患者。根据亚洲肌肉减少症工作组（AWGS）2019共识标准定义肌肉减少症。使用多变量逻辑回归模型计算T2DM患者总体及所有性别中Lp（a）≥30 mg/dL与肌肉减少症相关的比值比。还使用受限立方样条来评估Lp（a）与肌肉减少症之间的关联。

结果

426例患者中，平均年龄为58.6岁，男性占56.3%。总体患者中肌肉减少症的患病率为31.7%，男性为34.2%，女性为28.5%。总体患者中Lp（a）≥30 mg/dL的比例为19.0%。与Lp（a）<30 mg/dL组的患者相比，Lp（a）≥30 mg/dL组的患者肌肉减少症风险增加（调整后的比值比[aOR]：2.19，95%置信区间：1.09至4.39，p = 0.027）。受限立方样条的结果很可靠。分析各性别时，Lp（a）≥30 mg/dL与肌肉减少症之间也存在显著关联（男性：aOR：2.59，95%置信区间：1.09至6.21，p = 0.032；女性：aOR：2.45，95%置信区间：1.06至6.03，p = 0.039）。